ライフサイエンスコーパス: aborted cardiac arrest

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 alizations, 222 cardiovascular deaths, and 6 aborted cardiac arrests).

2 cardiovascular death, HF hospitalization, or aborted cardiac arrest.

3 lar death, heart failure hospitalization, or aborted cardiac arrest.

4 had at least 1 recurrence: 0 patients had an aborted cardiac arrest, 2 patients had syncope only, 10

5 Clinical and genetic risk factors for aborted cardiac arrest (ACA) or sudden cardiac death (SC

6 or (2) arrhythmogenic syncope, seizures, or aborted cardiac arrest after LCSD.

7 There were 81 patients who experienced aborted cardiac arrest and 45 who had sudden cardiac dea

8 There were 27 aborted cardiac arrest and 78 sudden cardiac death event

9 nual incidence rate for HCM-related SCD plus aborted cardiac arrest and HCM-related life-threatening

10 dpoint of cardiovascular (CV) death, HFH, or aborted cardiac arrest and key secondary outcomes, inclu

11 ngation, and sex were predictive of risk for aborted cardiac arrest and sudden cardiac death during a

12 Risk factors specific for aborted cardiac arrest and sudden cardiac death have not

13 To estimate the number of HCM-related aborted cardiac arrests and lives potentially saved by i

14 CM-related life-threatening arrhythmia (SCD, aborted cardiac arrest, and appropriate implantable card

15 lar death, heart failure hospitalization, or aborted cardiac arrest, and its components.

16 However, syncope, aborted cardiac arrest, and LQTS-related death continue

17 ted to the risk for cardiac events (syncope, aborted cardiac arrest, and sudden cardiac death) among

18 ed hazard of a composite of cardiac syncope, aborted cardiac arrest, and sudden cardiac death, but a

19 an adverse cardiac event, including syncope, aborted cardiac arrest, and sudden death, during and aft

20 incidence of long QT syndrome-related death, aborted cardiac arrest, and syncope.

21 rs for a severe arrhythmic events comprising aborted cardiac arrest, appropriate implantable cardiove

22 ed as LQTS-attributable syncope or seizures, aborted cardiac arrest, appropriate ventricular fibrilla

23 Patients with a history of aborted cardiac arrest before starting beta-blockers (n=

24 rdiac death; 9 of the 81 patients who had an aborted cardiac arrest event experienced subsequent sudd

25 he primary composite outcome (a composite of aborted cardiac arrest, hospitalization for heart failur

26 HF hospitalization, cardiovascular death, or aborted cardiac arrest in HFpEF independent of clinical

27 re hospitalization, cardiovascular death, or aborted cardiac arrest independent of clinical and labor

28 ospitalization, cardiovascular mortality, or aborted cardiac arrest), its components, and all-cause m

29 ure and death (n = 4), sudden death (n = 1), aborted cardiac arrest (n = 1), or heart transplantation

30 The risk of aborted cardiac arrest or death from age 41 though 75 ye

31 versus unaffected adjusted hazard ratio for aborted cardiac arrest or death was 2.65 (P<0.001) in th

32 zard ratio of 12.9 (95% CI, 4.7 to 35.5) for aborted cardiac arrest or death while on prescribed beta

33 tality or ventricular arrhythmia, defined as aborted cardiac arrest or documented ventricular fibrill

34 ons was associated with the highest risk for aborted cardiac arrest or sudden cardiac death (hazard r

35 gnificantly greater reduction in the risk of aborted cardiac arrest or sudden cardiac death among pat

36 Significant independent predictors of aborted cardiac arrest or sudden cardiac death during ad

37 deling was used to identify risk factors for aborted cardiac arrest or sudden cardiac death in 3015 L

38 a comprehensive analysis of risk factors for aborted cardiac arrest or sudden cardiac death in pre-sp

39 syncope, documented torsades de pointes, and aborted cardiac arrest or sudden cardiac death.

40 9.1) for recurrent cardiac events (syncope, aborted cardiac arrest, or death) during beta-blocker th

41 hmic event, defined as sudden cardiac death, aborted cardiac arrest, or hemodynamically unstable vent

42 osite outcome (time to cardiovascular death, aborted cardiac arrest, or hospitalization for managemen

43 outcome of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the manag

44 mposite of death from cardiovascular causes, aborted cardiac arrest, or hospitalization for the manag

45 vents arrhythmic events (arrhythmic syncope, aborted cardiac arrest, or sudden cardiac death) in LQT3

46 le cardioverter defibrillator (ICD) therapy, aborted cardiac arrest, or sudden cardiac death.

47 to 5% annual risk of LQTS-triggered syncope, aborted cardiac arrest, or sudden cardiac death.

48 ty and lethality of cardiac events (syncope, aborted cardiac arrest, or sudden death) occurring from

49 The probability of cardiac events (syncope, aborted cardiac arrest, or sudden death) was analyzed by

50 educing the risk of cardiac events (syncope, aborted cardiac arrest, sudden cardiac death).

51 0 [p < 0.0001]) and life-threatening events (aborted cardiac arrest/sudden cardiac death: 27% per 10-

52 cardioverter-defibrillator intervention, and aborted cardiac arrest was considered.